



Docket No.: 5000-0201PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Carsten BLETTNER et al.

Application No.: 10/594,738

Confirmation No.: 5297

Filed: September 29, 2006

Art Unit: 1614

For: 6-(2-FLUOROPHENYL)-

TRIAZOLOPYRIMIDINES, METHOD FOR PRODUCING THEM, THEIR USE FOR CONTROLLING PARASITIC FUNGI AND AGENTS CONTAINING THE SAME

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

a. Copies of cited U.S. patents and patent application publications are not included.

Copies of foreign patent documents and non-patent literature are included.

ADM/srm

Application No.: 10/594,738 Docket No.: 5000-0201PUS1

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

c. <u>REFERENCES PREVIOUSLY CITED OR SUBMITTED</u> - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. <u>DOCUMENTS IN THE ENGLISH LANGUAGE</u> The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.
- b. <u>DOCUMENTS NOT IN THE ENGLISH LANGUAGE</u> A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: An English language abstract is provided for JP 2002-308879-A, WO 2004/087705-A1, and WO 02/38565-A2.
- c. <u>ENGLISH LANGUAGE SEARCH REPORT</u> An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).
- d. OTHER The following additional information is provided for the Examiner's consideration. US 5,994,360-A is cited on page 2, line number 19 of the specification. WO/0238565-A2 corresponds to US 2004/110771-A1, US 2006/0135538-A1, and 6,855,718-B2 that is also cited on page 2, line number 20 of the specification. EP 1 002 788-A1 is cited on

2 ADM/srm

Application No.: 10/594,738 Docket No.: 5000-0201PUS1

page 3, line number 11, WO 98/46608-A1 is cited on page 4, line number 6, and EP 0 550 113-A3 of the specification. WO corresponds with CA 2 520 579-A1.

IV. <u>FEF</u>	S (check one box)
a. of a new pa	This Information Disclosure Statement is being filed concurrently with the filing tent application; therefore, no fee is required.
b.	This Information Disclosure Statement is being filed concurrent with the filing of on-in-part, continuation, or divisional patent application; therefore, no fee is required
-	This Information Disclosure Statement is being filed within three months of the of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required in is not to be used with RCE's.)
	This Information Disclosure Statement is being filed within three months of the y of the national stage as set forth in § 1.491 in an international application (37 C.F.R.). No fee or statement is required.
e. of a Requestatement is	This Information Disclosure Statement is being filed concurrently with the filing st for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee of required.
that a first (§ 1.97(c) a	This Information Disclosure Statement is being filed before the mailing date of a on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the even of the Action on the merits has been issued, please consider this IDS under 37 C.F.R. and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been go our deposit account for the fee as required by 37 C.F.R. § 1.17(p).
	This Information Disclosure Statement is being filed before the mailing date of a e Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing otice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

Application No.: 10/594,738 No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or See the statement below. No fee is required. STATEMENT UNDER 37 C.F.R. § 1.97(e) V. (check only one box) The undersigned hereby states that: Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or Each item of information contained in the IDS was first cited in any b. communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or No item of information contained in the IDS was cited in a communication from a c. foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. Some of the items of information were cited in a communication from a foreign d. Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable

> ADM/srm 4

Docket No.: 5000-0201PUS1

Application No.: 10/594,738 Docket No.: 5000-0201PUS1

inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

The required fee is listed on the attached Fee Transmitt	al.
--	-----

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: November 14, 2006

Respectfully submitted,

Andrew D. Meikle

Registration No.: 32,868

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East P.O. Box 747

By

Falls Church, Virginia 22040-0747

(703) 205-8000

5

Attorney for Applicant

Attachment(s):

✓ PTO-SB08✓ Documents

Foreign Search Report



PTO/SB/08A/B (09-06) Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE juction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
Substitute for form 1445/1 10				Application Number	10/594,738
INFORMATION DISCLOSURE				Filing Date	September 29, 2006
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Carsten BLETTNER
	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1614
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	5000-0201PUS1

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	AA*	US-5,994,360-A	11-30-1999	Pfrengle et al.	
	AB*	US-2004/0110771-A1	06-10-2004	Blasco et al.	
	AC*	US-6,855,718-B2	02-15-2005	Blasco et al.	
	AD*	US-2006/0135538-A1	06-22-2006	Blasco et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T⁵
	ВА	CA-2 520 579-A1	10-14-2004			
	ВВ	WO-2004/087705-A	10-14-2004			Ш
	ВС	WO-03/008415-A1	01-30-2003			
	BD	JP-2002-308879-A	10-23-2002			
	BE	WO-02/083677-A1	10-24-2002			
	BF	FR-2 765 875-A1	01-15-1999			
	BG	EP-0 550 113-A3	10-15-1997			
	ВН	WO-98/46608-A1	10-22-1998	American Cyanamid Co		
	ВІ	EP-1 002 788-A1	05-24-2000			
	BJ	WO-02/38565-A2	05-16-2002	Basf Ag et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Date Considered
Birch Stewart Kolasch & Birch LLP	ADM/srm

Birch, Stewart, Kolasch & Birch, LLP

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.